Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.

Lunati ME, Cimino V, Bernasconi D, Gandolfi A, Morpurgo PS, Tinari C, Lazzaroni E, Baruffaldi L, Muratori M, Montefusco L, Pastore I, Rossi A and 14 more

Show all authors

Franzetti IG, Muratori F, Manfrini R, Disoteo OE, Terranova R, Desenzani P, Girelli A, Ghelardi R, D'Addio F, Ben Nasr M, Berra C, Folli F, Bucciarelli L, Fiorina P

Pharmacological research20 Dec 2023Cited by 27 (Europe PMC)

PMID38128857DOI10.1016/j.phrs.2023.107040PepBankPUB-38128857

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in an observational study, oral semaglutide added to dapagliflozin was associated with an HbA1c reduction of 1.2% versus 0.5% with dapagliflozin alone at 6 months.
In plain wordsIn adults with type 2 diabetes, HbA1c fell by 1.2% with oral semaglutide plus dapagliflozin, compared with 0.5% with dapagliflozin alone.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction at 6 months
Study
n = 1,335
Comparator
Dapagliflozin alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral · 6 monthsAs given in this study (human).
Measurements
HbA1c reduction
1.2%
dapagliflozin plus oral semaglutide
HbA1c reduction
0.5%
dapagliflozin alone
Source sentences
Summary
the treatment with dapagliflozin plus oral semaglutide showed a reduction of glycated hemoglobin of 1.2% as compared to the 0.5% reduction observed in the dapagliflozin alone group.
2 context sentences(design, population, supporting numbers)
Summary · context
We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
Summary · context
A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide.
Report a problemFND-3812885701

Studies that did not test the peptide alone7

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, 55% reached near-normalization of HbA1c; the abstract does not say which treatment group this covers.
In plain wordsIn adults with type 2 diabetes, 55% reached near-normal HbA1c. The abstract does not say which treatment group this covers.
Peptide
Semaglutide
Outcome
Not applicableNear-normalization of HbA1c
Study
n = 1,335
Outcome group
Glycemic control · Metabolic and weight
Measurements
Near-normalization of HbA1c
55%
group not stated
Source sentences
Summary
with a high rate (55%) of near-normalization of glycated hemoglobin.
2 context sentences(design, population, supporting numbers)
Summary · context
We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
Summary · context
A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3812885702
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, body mass index changed significantly; the abstract gives no direction or group.
In plain wordsIn adults with type 2 diabetes, body mass index changed significantly. The abstract does not say in which direction or group.
Peptide
Semaglutide
Outcome
Direction not reportedChange in body mass index
Study
n = 1,335
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Significant changes were observed in body mass index
2 context sentences(design, population, supporting numbers)
Summary · context
We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
Summary · context
A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3812885703
04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, fasting plasma glucose changed significantly; the abstract gives no direction or group.
In plain wordsIn adults with type 2 diabetes, fasting blood glucose changed significantly. The abstract does not say in which direction or group.
Peptide
Semaglutide
Outcome
Direction not reportedChange in fasting plasma glucose
Study
n = 1,335
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Significant changes were observed in body mass index, fasting plasmatic glucose
2 context sentences(design, population, supporting numbers)
Summary · context
We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
Summary · context
A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3812885704
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, blood pressure changed significantly; the abstract gives no direction or group.
In plain wordsIn adults with type 2 diabetes, blood pressure changed significantly. The abstract does not say in which direction or group.
Peptide
Semaglutide
Outcome
Direction not reportedChange in blood pressure
Study
n = 1,335
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Significant changes were observed in body mass index, fasting plasmatic glucose, blood pressure
2 context sentences(design, population, supporting numbers)
Summary · context
We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
Summary · context
A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3812885705
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, total cholesterol changed significantly; the abstract gives no direction or group.
In plain wordsIn adults with type 2 diabetes, total cholesterol changed significantly. The abstract does not say in which direction or group.
Peptide
Semaglutide
Outcome
Direction not reportedChange in total cholesterol
Study
n = 1,335
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Significant changes were observed in body mass index, fasting plasmatic glucose, blood pressure, total cholesterol
2 context sentences(design, population, supporting numbers)
Summary · context
We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
Summary · context
A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3812885706
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, LDL cholesterol changed significantly; the abstract gives no direction or group.
In plain wordsIn adults with type 2 diabetes, LDL cholesterol changed significantly. The abstract does not say in which direction or group.
Peptide
Semaglutide
Outcome
Direction not reportedChange in LDL cholesterol
Study
n = 1,335
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Significant changes were observed in body mass index, fasting plasmatic glucose, blood pressure, total cholesterol, LDL
2 context sentences(design, population, supporting numbers)
Summary · context
We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
Summary · context
A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3812885707
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes, the albumin to creatinine ratio changed significantly; the abstract gives no direction or group.
In plain wordsIn adults with type 2 diabetes, the urine albumin to creatinine ratio changed significantly. The abstract does not say in which direction or group.
Peptide
Semaglutide
Outcome
Direction not reportedChange in albumin to creatinine ratio
Study
n = 1,335
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
albumin to creatinine ratio
2 context sentences(design, population, supporting numbers)
Summary · context
We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
Summary · context
A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3812885708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.